Literature DB >> 1999656

In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje.

C W Van den Berg1, P C Aerts, H Van Dijk.   

Abstract

The kinetics of complement (C) depletion and recovery of C levels upon injection of BALB/c mice with cobra venom factors (CVF), from N. naja (C3- and C5-depleting) and N. haje (selectively C3-depleting) were studied. The animals received i.p. or i.v. injections of either of the two preparations. CH50 and hemolytic C3 and C5 levels were followed as parameters of residual complement activity. N. naja CVF turned out to be as efficient in depleting total complement activity as N. haje CVF. Decreased CH50 values could largely be ascribed to C3 depletion. Complement consumption after N. naja CVF, however, lasted longer than after N. haje CVF administration. Estimated functional half-lives of N. naja and N. haje CVF were 11.5 and 4.5 h, respectively. Inhibition ELISAs showed that, after in vivo administration of either of the two CVF preparations, antigenic C3 and C5 kept circulating for days.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1999656     DOI: 10.1016/0022-1759(91)90015-8

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  22 in total

Review 1.  B1b lymphocyte-derived antibodies control Borrelia hermsii independent of Fcα/μ receptor and in the absence of host cell contact.

Authors:  Matthew J Colombo; David Abraham; Akira Shibuya; Kishore R Alugupalli
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

2.  Autoantibodies contribute to the immunopathogenesis of experimental dry eye disease.

Authors:  Michael E Stern; Chris S Schaumburg; Karyn F Siemasko; Jianping Gao; Larry A Wheeler; Devin A Grupe; Cintia S De Paiva; Virginia L Calder; Margarita Calonge; Jerry Y Niederkorn; Stephen C Pflugfelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-24       Impact factor: 4.799

3.  Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody.

Authors:  Ankur B Dalia; Jeffrey N Weiser
Journal:  Cell Host Microbe       Date:  2011-11-17       Impact factor: 21.023

4.  Role of complement in C-reactive-protein-mediated protection of mice from Streptococcus pneumoniae.

Authors:  A J Szalai; D E Briles; J E Volanakis
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

5.  Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Authors:  Carolina Salcedo-Rivillas; Anne-Sophie Debrie; Eliane Namie Miyaji; Jorge M C Ferreira; Isaías Raw; Camille Locht; Paulo L Ho; Nathalie Mielcarek; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

6.  Complexity of Complement Resistance Factors Expressed by Acinetobacter baumannii Needed for Survival in Human Serum.

Authors:  Amaro F Sanchez-Larrayoz; Noha M Elhosseiny; Marc G Chevrette; Yang Fu; Peter Giunta; Raúl G Spallanzani; Keerthikka Ravi; Gerald B Pier; Stephen Lory; Tomás Maira-Litrán
Journal:  J Immunol       Date:  2017-08-30       Impact factor: 5.422

7.  Complement C3 is required for the progression of cutaneous lesions and neutrophil attraction in Leishmania major infection.

Authors:  Thomas Jacobs; Jörg Andrä; Iris Gaworski; Sebastian Graefe; Katja Mellenthin; Manfred Krömer; Roman Halter; Jürgen Borlak; Joachim Clos
Journal:  Med Microbiol Immunol       Date:  2004-09-17       Impact factor: 3.402

8.  The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement.

Authors:  Alexander Bukreyev; Lijuan Yang; Peter L Collins
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

9.  Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

Authors:  Veronique Minard-Colin; Yan Xiu; Jonathan C Poe; Mayuka Horikawa; Cynthia M Magro; Yasuhito Hamaguchi; Karen M Haas; Thomas F Tedder
Journal:  Blood       Date:  2008-05-21       Impact factor: 22.113

10.  C3- and T-cell-dependent adjuvant activity of in vivo formed immune complexes.

Authors:  C W Van den Berg; M A Hazenberg; F M Hofhuis; S M Van Rooyen; H Van Dijk
Journal:  Immunology       Date:  1991-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.